Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar- ustekinumab) in the US
Shots:
- Bio-Thera to receive $20M up front and $130M as development and commercial milestones and will be responsible for the development- manufacturing- and supply of BAT2206
- Hikma get exclusive rights to commercialize the biosimilar in the US and received first-right-to-negotiate to add Europe (excluding CIS countries)
- BAT2206 is a mAb- that is a proposed biosimilar referencing Janssen’s Stelara (ustekinumab) and is currently in a global P-III clinical trial
| Ref: Businesswire | Image: Hikma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
